Tideglusib
Sponsors
Noscira SA, Holland Bloorview Kids Rehabilitation Hospital, AMO Pharma Limited, University of Zurich, Hamilton Health Sciences Corporation
Conditions
Alzheimer's DiseaseAmyotrophic Lateral SclerosisArrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular CardiomyopathyAutism Spectrum DisordersCongenital Myotonic DystrophyMyotonic Dystrophy 1Progressive Supranuclear Palsy
Phase 2
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
CompletedNCT01350362
Start: 2011-04-30End: 2012-10-31Updated: 2012-10-02
Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders
CompletedNCT02586935
Start: 2016-02-10End: 2018-02-25Updated: 2025-07-16
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
CompletedNCT02858908
Start: 2016-07-20End: 2018-01-31Updated: 2025-09-11
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
CompletedNCT03692312
Start: 2021-03-03End: 2023-04-04Updated: 2025-10-08
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
RecruitingNCT05004129
Start: 2021-08-23End: 2026-12-31Target: 76Updated: 2025-05-28
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
Not yet recruitingNCT05105958
Start: 2025-12-01End: 2026-03-01Target: 98Updated: 2025-01-28
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
RecruitingNCT06174220
Start: 2025-03-21End: 2027-07-01Target: 120Updated: 2026-03-12
Unknown Phase
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
CompletedNCT01049399
Start: 2009-12-31End: 2011-11-30Updated: 2012-01-05
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
NCT07119775
Updated: 2025-08-13